1. Dipòsit Digital de la Universitat de Barcelona
  2. Recerca
  3. Farmàcia, Tecnologia Farmacèutica i Fisicoquímica
  4. Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)
Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/166339
Full metadata record
DC FieldValueLanguage
dc.contributor.authorVieira, Raquel-
dc.contributor.authorSouto, Selma B.-
dc.contributor.authorSánchez-López, E. (Elena)-
dc.contributor.authorLópez-Machado, Ana-
dc.contributor.authorSeverino, Patrícia-
dc.contributor.authorJose, Sajan-
dc.contributor.authorSantini, Antonello-
dc.contributor.authorSilva, Amélia M.-
dc.contributor.authorFortiuna, Ana-
dc.contributor.authorGarcía López, María Luisa-
dc.contributor.authorSouto, Eliana B.-
dc.date.accessioned2020-06-19T14:59:30Z-
dc.date.available2020-06-19T14:59:30Z-
dc.date.issued2019-08-28-
dc.identifier.issn2077-0383-
dc.identifier.urihttp://hdl.handle.net/2445/166339-
dc.description.abstractDiabetes is a complex disease characterized by hyperglycemia, together with polyuria, polydipsia, and polyphagia. While Type 1 diabetes mellitus (T1DM) results from genetic, environmental, or immune dysfunction factors leading to pancreatic β-cell destruction depriving the organism from endogenous insulin, Type 2 diabetes mellitus (T2DM) is characterized by peripheral insulin resistance. Depending on the type of diabetes mellitus and drug mechanism to study, the animal model should be carefully selected among the wide variety of the currently available ones. This review discusses the most common animal models currently employed to study T1DM and T2DM. Moreover, an overview on the administration routes that could be used is also discussed.-
dc.format.extent20 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherMDPI-
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3390/jcm8091332-
dc.relation.ispartofJournal of Clinical Medicine, 2019, vol. 8, num. 9, p. 1332-
dc.relation.urihttps://doi.org/10.3390/jcm8091332-
dc.rightscc-by (c) Vieira, Raquel et al., 2019-
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es-
dc.sourceArticles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)-
dc.subject.classificationDiabetis no-insulinodependent-
dc.subject.classificationResistència a la insulina-
dc.subject.classificationFarmacologia-
dc.subject.classificationAnimals-
dc.subject.otherNon-insulin-dependent diabetes-
dc.subject.otherInsulin resistance-
dc.subject.otherPharmacology-
dc.subject.otherAnimals-
dc.titleSugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome Strategies for In Vivo Administration: Part-II-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.identifier.idgrec701303-
dc.date.updated2020-06-19T14:59:31Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.identifier.pmid31466386-
Appears in Collections:Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)
Articles publicats en revistes (Institut de Nanociència i Nanotecnologia (IN2UB))

Files in This Item:
File Description SizeFormat 
701303.pdf653.74 kBAdobe PDFView/Open
Show simple item record


This item is licensed under a Creative Commons License Creative Commons